

Takaki Yoshikawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8108407/publications.pdf>

Version: 2024-02-01

310
papers

9,962
citations

71102

41
h-index

45317

90
g-index

323
all docs

323
docs citations

323
times ranked

9000
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of renal function with the safety and efficacy of cisplatin plus S-1 therapy and docetaxel plus cisplatin plus S-1 therapy in patients with advanced gastric cancer: an exploratory analysis of JCOG1013. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 14-23.	1.3	0
2	Optimal surgery and lymph node metastasis of duodenal bulbar neuroendocrine neoplasms. <i>European Journal of Surgical Oncology</i> , 2022, 48, 597-603.	1.0	0
3	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2022, 25, 207-217.	5.3	9
4	Negative impact of intraoperative blood loss on long-term outcome after curative gastrectomy for advanced gastric cancer: exploratory analysis of the JCOG1001 phase III trial. <i>Gastric Cancer</i> , 2022, 25, 459-467.	5.3	9
5	Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinoma. <i>British Journal of Surgery</i> , 2022, 109, 291-297.	0.3	4
6	Prediction of the peritoneal recurrence via the macroscopic diagnosis of the serosal invasion in patients with gastric cancer: Supplementary analysis of JCOG0110. <i>European Journal of Surgical Oncology</i> , 2022, , .	1.0	1
7	Suprapancreatic nodal dissection should not be uniformly selected in additional gastrectomy for the patients who diagnosed as pT1b gastric cancer by endoscopic resection. <i>European Journal of Surgical Oncology</i> , 2022, , .	1.0	0
8	Reply to: Letter to the Editor "Suprapancreatic nodal dissection should not be uniformly selected in additional gastrectomy for the patients diagnosed as pT1b gastric cancer by endoscopic resection". <i>European Journal of Surgical Oncology</i> , 2022, , .	1.0	0
9	Surgical and perioperative treatment strategy for resectable esophagogastric junction cancer. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 417-424.	1.3	6
10	A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. <i>Gastric Cancer</i> , 2022, 25, 619-628.	5.3	18
11	Effects of perioperative eicosapentaenoic acid-enriched oral nutritional supplement on the long-term oncological outcomes after total gastrectomy for gastric cancer. <i>Oncology Letters</i> , 2022, 23, .	1.8	5
12	Author response to: Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinoma. <i>British Journal of Surgery</i> , 2022, , .	0.3	0
13	Impact of tumor-related factors and inter-institutional heterogeneity on preoperative T staging for gastric cancer. <i>Future Oncology</i> , 2022, 18, 2511-2519.	2.4	3
14	Gastric cancer biomarker analysis in patients treated with different adjuvant chemotherapy regimens within SAMIT, a phase III randomized controlled trial. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
15	Feasibility and Safety of Oral Nutritional Supplementation with High-Density Liquid Diet After Total Gastrectomy for Gastric Cancer. <i>World Journal of Surgery</i> , 2022, 46, 2433-2439.	1.6	0
16	Should the splenic hilar lymph node be dissected for the management of adenocarcinoma of the esophagogastric junction?. <i>European Journal of Surgical Oncology</i> , 2022, , .	1.0	0
17	Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors. <i>Annals of Surgery</i> , 2021, 274, 120-127.	4.2	138
18	Impact of postoperative complications on survival outcomes in patients with gastric cancer: exploratory analysis of a randomized controlled JCOG1001 trial. <i>Gastric Cancer</i> , 2021, 24, 214-223.	5.3	32

#	ARTICLE	IF	CITATIONS
19	Survival analysis of a prospective multicenter observational study on surgical palliation among patients receiving treatment for malignant gastric outlet obstruction caused by incurable advanced gastric cancer. <i>Gastric Cancer</i> , 2021, 24, 224-231.	5.3	10
20	Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. <i>Gastric Cancer</i> , 2021, 24, 492-502.	5.3	79
21	Current status of immunotherapy for advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 20-27.	1.3	43
22	Intraoperative blood loss as an independent prognostic factor for curative resection after neoadjuvant chemotherapy for gastric cancer: a single-center retrospective cohort study. <i>Surgery Today</i> , 2021, 51, 293-302.	1.5	2
23	Short-term Outcomes from a Randomized Screening Phase II Non-inferiority Trial Comparing Omentectomy and Omentum Preservation for Locally Advanced Gastric Cancer: the TOP Trial. <i>World Journal of Surgery</i> , 2021, 45, 1803-1811.	1.6	17
24	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer</i> , 2021, 24, 946-958.	5.3	61
25	QOL assessment after palliative surgery for malignant bowel obstruction caused by peritoneal dissemination of gastric cancer: a prospective multicenter observational study. <i>Gastric Cancer</i> , 2021, 24, 1131-1139.	5.3	5
26	Pathological complete response at the para-aortic nodes as a possible surrogate endpoint in gastric cancer surgery with para-aortic node dissection after neoadjuvant chemotherapy. <i>European Journal of Surgical Oncology</i> , 2021, , .	1.0	0
27	Clinical biomarkers in adjuvant chemotherapy for gastric cancer after D2 dissection by a pooled analysis of individual patient data from large randomized controlled trials. <i>Gastric Cancer</i> , 2021, 24, 1184-1193.	5.3	5
28	Is lymph node dissection for neuroendocrine carcinoma of the stomach effective as it is for adenocarcinoma?. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2004-2009.	1.0	3
29	The prognostic impact of macroscopic serosal change on resectable advanced gastric cancer. <i>BMC Cancer</i> , 2021, 21, 1056.	2.6	2
30	Evaluation of Lymph Node Staging Systems as Independent Prognosticators in Remnant Gastric Cancer Patients with an Insufficient Number of Harvested Lymph Nodes. <i>Annals of Surgical Oncology</i> , 2021, 28, 2866-2876.	1.5	9
31	Optimal surgery for esophagogastric junctional cancer. <i>Langenbeck's Archives of Surgery</i> , 2021, , 1.	1.9	4
32	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020, 23, 143-153.	5.3	45
33	Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial. <i>International Journal of Clinical Oncology</i> , 2020, 25, 301-311.	2.2	8
34	An easy and reliable method to close Petersen's defect using barbed suture to prevent internal hernia from developing after gastrectomy with Roux-Y reconstruction. <i>Asian Journal of Endoscopic Surgery</i> , 2020, 13, 238-241.	0.9	6
35	Different risks of nodal metastasis by tumor location in remnant gastric cancer after curative gastrectomy for gastric cancer. <i>Gastric Cancer</i> , 2020, 23, 195-201.	5.3	6
36	Is surgery alone sufficient for treating T1 gastric cancer with extensive lymph node metastases?. <i>Gastric Cancer</i> , 2020, 23, 349-355.	5.3	16

#	ARTICLE	IF	CITATIONS
37	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020, 23, 510-519.	5.3	155
38	High gamma-glutamyl hydrolase and low folylpolyglutamate synthetase expression as prognostic biomarkers in patients with locally advanced gastric cancer who were administered postoperative adjuvant chemotherapy with S-1. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 75-86.	2.5	8
39	Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 142-151.	8.1	188
40	Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer. <i>European Journal of Cancer</i> , 2020, 124, 67-76.	2.8	16
41	Predictive value of the surgical Apgar score on postoperative complications in advanced gastric cancer patients treated with neoadjuvant chemotherapy followed by radical gastrectomy: a single-center retrospective study. <i>BMC Surgery</i> , 2020, 20, 150.	1.3	2
42	The Impact of Severe Infectious Complications on Long-term Prognosis for Gastric Cancer. <i>Anticancer Research</i> , 2020, 40, 4067-4074.	1.1	8
43	Primary results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S1 and docetaxel/cisplatin/S1 as neoadjuvant chemotherapy for advanced gastric cancer. <i>Annals of Gastroenterological Surgery</i> , 2020, 4, 540-548.	2.4	10
44	The Clinical Significance of Lymphovascular Invasion in Gastric Cancer. <i>In Vivo</i> , 2020, 34, 1533-1539.	1.3	18
45	Differences in disease status between patients with progression after first-line chemotherapy versus early relapse after adjuvant chemotherapy who undergo second-line chemotherapy for gastric cancer: Exploratory analysis of the randomized phase III TRICS trial. <i>European Journal of Cancer</i> , 2020, 132, 159-167.	2.8	2
46	Association Between Lymph Node Ratio and Survival in Patients with Pathological Stage II/III Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 4235-4247.	1.5	27
47	Risk factors analysis and stratification for microscopically positive resection margin in gastric cancer patients. <i>BMC Surgery</i> , 2020, 20, 95.	1.3	10
48	Diagnosis of invasion depth in resectable advanced gastric cancer for neoadjuvant chemotherapy: An exploratory analysis of Japan clinical oncology group study: JCOG1302A. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1074-1079.	1.0	6
49	Current status of perioperative chemotherapy for locally advanced gastric cancer and JCOG perspectives. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 528-534.	1.3	19
50	Is splenectomy for dissecting splenic hilar lymph nodes justified for scirrhous gastric cancer?. <i>Gastric Cancer</i> , 2020, 23, 922-926.	5.3	8
51	A nodal diagnosis by computed tomography is unreliable for patients who need additional gastrectomy after endoscopic submucosal dissection. <i>Surgery Today</i> , 2020, 50, 1032-1038.	1.5	2
52	Randomized controlled Phase III trial to evaluate omentum preserving gastrectomy for patients with advanced gastric cancer (JCOG1711, ROAD-GC). <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1321-1324.	1.3	17
53	The Impact of Intraoperative Blood Loss on the Long-term Prognosis after Curative Resection for Borrmann Type IV Gastric Cancer: A Retrospective Multicenter Study. <i>Anticancer Research</i> , 2020, 40, 405-412.	1.1	7
54	Effect of Muscle Mass Loss After Esophagectomy on Prognosis of Oesophageal Cancer. <i>Anticancer Research</i> , 2020, 40, 2275-2281.	1.1	2

#	ARTICLE	IF	CITATIONS
55	Impact of Postoperative Complications on Recurrence in Patients With Stage II/III Gastric Cancer Who Received Adjuvant Chemotherapy With S-1. <i>Anticancer Research</i> , 2020, 40, 1683-1690.	1.1	3
56	The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuvant chemotherapy. <i>Journal of Cancer Research and Therapeutics</i> , 2020, 16, 116.	0.9	6
57	Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial. <i>Oncotarget</i> , 2020, 11, 2906-2918.	1.8	4
58	Questionnaire survey on adjuvant chemotherapy for elderly patients after gastrectomy indicates their vulnerabilities. <i>Gastric Cancer</i> , 2019, 22, 130-137.	5.3	6
59	Changes in bone metabolism after gastric cancer surgery in male patients: a prospective observational study. <i>Gastric Cancer</i> , 2019, 22, 237-243.	5.3	16
60	Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia. <i>JAMA Network Open</i> , 2019, 2, e198243.	5.9	25
61	The postoperative lean body mass loss at one month leads to a poor survival in patients with locally advanced gastric cancer. <i>Journal of Cancer</i> , 2019, 10, 2450-2456.	2.5	11
62	Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 501-510.	8.1	88
63	Impact of the Age-adjusted Charlson comorbidity index on the short- and long-term outcomes of patients undergoing curative gastrectomy for gastric cancer. <i>Journal of Cancer</i> , 2019, 10, 5527-5535.	2.5	35
64	Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104). <i>Hepatology</i> , 2019, 4, 208-216.	8.1	73
65	Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. <i>Nature Medicine</i> , 2019, 25, 1054-1056.	30.7	773
66	KRAS status is related to histological phenotype in gastric cancer: results from a large multicentre study. <i>Gastric Cancer</i> , 2019, 22, 1193-1203.	5.3	16
67	ASO Author Reflections: Splenic Hilar Nodal Dissection for Proximal Advanced Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 588-589.	1.5	2
68	Effects of perioperative Eicosapentaenoic acid-enriched oral nutritional supplement on lean body mass after total gastrectomy for gastric cancer. <i>Journal of Cancer</i> , 2019, 10, 1070-1076.	2.5	24
69	Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). <i>Gastric Cancer</i> , 2019, 22, 1044-1052.	5.3	89
70	Postoperative Level of C-Reactive Protein Is a Prognosticator After Esophageal Cancer Surgery With Perioperative Steroid Therapy and Enhanced Recovery After Surgery Care. <i>In Vivo</i> , 2019, 33, 587-594.	1.3	7
71	Clinical impact of splenic hilar dissection with splenectomy for gastric stump cancer. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1505-1510.	1.0	7
72	Does neoadjuvant chemotherapy cancel out the negative survival impact induced by surgical complications after gastrectomy?. <i>Gastric Cancer</i> , 2019, 22, 1274-1284.	5.3	6

#	ARTICLE	IF	CITATIONS
73	Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 1296-1304.	1.6	258
74	Single-arm confirmatory trial of laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer: Japan Clinical Oncology Group study JCOG1401. <i>Gastric Cancer</i> , 2019, 22, 999-1008.	5.3	115
75	Current status of the "enhanced recovery after surgery" program in gastric cancer surgery. <i>Annals of Gastroenterological Surgery</i> , 2019, 3, 231-238.	2.4	29
76	Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 1029-1035.	5.3	50
77	A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 867-874.	2.3	4
78	KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. <i>Future Oncology</i> , 2019, 15, 943-952.	2.4	133
79	<i>Helicobacter pylori</i> eradication treatment for gastric carcinoma prevention in asymptomatic or dyspeptic adults: systematic review and Bayesian meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2019, 9, e026002.	1.9	6
80	Clinical Significance of KIAA1199 as a Novel Target for Gastric Cancer Drug Therapy. <i>Anticancer Research</i> , 2019, 39, 6567-6573.	1.1	10
81	Safety and Feasibility of Linear Stapling Device with Bioabsorbable Polyglycolic Acid Sheet for Duodenal Closure in Gastric Cancer Surgery: A Multi-institutional Phase II Study. <i>World Journal of Surgery</i> , 2019, 43, 192-198.	1.6	6
82	Equivalent feasibility and safety of perioperative care by ERAS in open and laparoscopy-assisted distal gastrectomy for gastric cancer: a single-institution ancillary study using the patient cohort enrolled in the JCOG0912 phase III trial. <i>Gastric Cancer</i> , 2019, 22, 617-623.	5.3	16
83	The Therapeutic Survival Benefit of Splenic Hilar Nodal Dissection for Advanced Proximal Gastric Cancer Invading the Greater Curvature. <i>Annals of Surgical Oncology</i> , 2019, 26, 829-835.	1.5	33
84	Comparison of Weight and Body Composition After Gastrectomy Between Elderly and Non-elderly Patients With Gastric Cancer. <i>In Vivo</i> , 2019, 33, 221-227.	1.3	15
85	Long-term quality of life and nutrition status of the aboral pouch reconstruction after total gastrectomy for gastric cancer: a prospective multicenter observational study (CCOG1505). <i>Gastric Cancer</i> , 2019, 22, 607-616.	5.3	21
86	A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). <i>Gastric Cancer</i> , 2019, 22, 344-354.	5.3	60
87	Influence of Postoperative Surgical Complications After Gastrectomy on Body Weight and Body Composition Changes in Patients With Gastric Cancer. <i>Anticancer Research</i> , 2019, 39, 1073-1078.	1.1	4
88	The impact of infectious complications on long-term prognosis after curative resection for gastric cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 122-122.	1.6	0
89	A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XPaTS-I trial. <i>Gastric Cancer</i> , 2018, 21, 811-818.	5.3	11
90	An ancillary biomarker study in the SAMIT randomized trial: Sequential paclitaxel followed by UFT or S-1 versus UFT or S-1 alone as adjuvant chemotherapy for T4a/b gastric cancer. <i>Annals of Cancer Research and Therapy</i> , 2018, 26, 39-42.	0.3	1

#	ARTICLE	IF	CITATIONS
91	Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 460-468.	8.1	102
92	A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: final results of the INPACT trial. <i>Gastric Cancer</i> , 2018, 21, 1014-1023.	5.3	34
93	Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 803-808.	1.3	36
94	Clinical Signatures of Mucinous and Poorly Differentiated Subtypes of Colorectal Adenocarcinomas by a Propensity Score Analysis of an Independent Patient Database from Three Phase III Trials. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 461-471.	1.3	12
95	Long-term outcomes of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG0703). <i>Gastric Cancer</i> , 2018, 21, 155-161.	5.3	61
96	A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). <i>Gastric Cancer</i> , 2018, 21, 68-73.	5.3	110
97	Frequent Coamplification of Receptor Tyrosine Kinase and Downstream Signaling Genes in Japanese Primary Gastric Cancer and Conversion in Matched Lymph Node Metastasis. <i>Annals of Surgery</i> , 2018, 267, 114-121.	4.2	15
98	Risk factors for severe weight loss at 1 month after gastrectomy for gastric cancer. <i>Asian Journal of Surgery</i> , 2018, 41, 349-355.	0.4	14
99	Randomized phase III trial comparing surgery alone to UFT+PSK for stage II rectal cancer (JFMC38 trial). <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 65-71.	2.3	11
100	Effects of goal-directed fluid therapy on enhanced postoperative recovery: An interventional comparative observational study with a historical control group on oesophagectomy combined with ERAS program. <i>Clinical Nutrition ESPEN</i> , 2018, 23, 184-193.	1.2	25
101	Priority of lymph node dissection for proximal gastric cancer invading the greater curvature. <i>Gastric Cancer</i> , 2018, 21, 569-572.	5.3	31
102	A Comparison of the Body Composition Changes Between Laparoscopy-assisted and Open Total Gastrectomy for Gastric Cancer. <i>In Vivo</i> , 2018, 32, 1513-1518.	1.3	9
103	A phase III trial to confirm modified S-1 adjuvant chemotherapy for pathological stage II/III vulnerable elderly gastric cancer patients who underwent gastric resection (JCOG1507, BIRDIE). <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 1101-1104.	1.3	7
104	Identification of a high-risk subtype of intestinal-type Japanese gastric cancer by quantitative measurement of the luminal tumor proportion. <i>Cancer Medicine</i> , 2018, 7, 4914-4923.	2.8	25
105	Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol. <i>BMC Cancer</i> , 2018, 18, 186.	2.6	6
106	The Negative Survival Impact of Infectious Complications After Surgery is Canceled Out by the Response of Neoadjuvant Chemotherapy in Patients with Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 2034-2043.	1.5	11
107	Clinical significance of secreted protein, acidic and cysteine-rich gene expression in patients with stage II/III gastric cancer following curative resection and adjuvant chemotherapy with S-1. <i>Oncology Letters</i> , 2018, 15, 7335-7343.	1.8	2
108	Our connection procedure for an EEA XL stapler and anvil head using EEA OrVil for laparoscopic total or proximal gastrectomy. <i>Asian Journal of Endoscopic Surgery</i> , 2018, 11, 280-283.	0.9	1

#	ARTICLE	IF	CITATIONS
109	The Lymph Node Ratio Is an Independent Prognostic Factor in Pancreatic Cancer Patients Who Receive Curative Resection Followed by Adjuvant Chemotherapy. <i>Anticancer Research</i> , 2018, 38, 4877-4882.	1.1	25
110	The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C). <i>Journal of Cancer</i> , 2018, 9, 1725-1730.	2.5	17
111	A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II). <i>European Journal of Cancer</i> , 2018, 101, 220-228.	2.8	11
112	Does a laparoscopic approach attenuate the body weight loss and lean body mass loss observed in open distal gastrectomy for gastric cancer? a single-institution exploratory analysis of the JCOG 0912 phase III trial. <i>Gastric Cancer</i> , 2018, 21, 345-352.	5.3	14
113	Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer: Japan Clinical Oncology Group study (JCOG0501).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4046-4046.	1.6	28
114	A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundation for Multidisciplinary) Tj ETQq0 0 0 rgBT /Overlock 10 ⁶ f 50 532	0.9	6
115	Survival and the prognosticators of peritoneal cytology-positive pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 1129.	0.9	5
116	Identification of clinical biomarkers for adjuvant chemotherapy in gastric cancer after D2 dissection by pooled analysis of individual patient data from three large randomized clinical trials. <i>Annals of Cancer Research and Therapy</i> , 2018, 26, 43-45.	0.3	1
117	Evaluation of clinic pathological characteristics and prognosis of gastric cancer in elderly patients. <i>Annals of Cancer Research and Therapy</i> , 2018, 26, 31-32.	0.3	0
118	The relation between Age-adjusted Charlson comorbidity index and gastric cancer survival. <i>Annals of Cancer Research and Therapy</i> , 2018, 26, 17-18.	0.3	0
119	A Case of Intrapelvic Desmoid Tumor Occurring 2 years after Laparoscopic Assisted Total Gastrectomy. <i>Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)</i> , 2018, 43, 273-278.	0.0	1
120	Long-term prognosis of α -fetoprotein-producing gastric cancer defined as immunohistochemical expression.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16036-e16036.	1.6	0
121	Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. <i>Gastric Cancer</i> , 2017, 20, 175-181.	5.3	77
122	Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study. <i>Gastric Cancer</i> , 2017, 20, 332-340.	5.3	63
123	Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial. <i>Gastric Cancer</i> , 2017, 20, 190-199.	5.3	27
124	Changes in fat-soluble vitamin levels after gastrectomy for gastric cancer. <i>Surgery Today</i> , 2017, 47, 145-150.	1.5	18
125	Clinical significance of platelet-derived growth factor receptor- β gene expression in stage II/III gastric cancer with S-1 adjuvant chemotherapy. <i>Oncology Letters</i> , 2017, 13, 905-911.	1.8	12
126	Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. <i>Gastric Cancer</i> , 2017, 20, 904-912.	5.3	33

#	ARTICLE	IF	CITATIONS
127	Adjuvant therapy for locally advanced gastric cancer. <i>Surgery Today</i> , 2017, 47, 1295-1302.	1.5	52
128	Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer. <i>International Journal of Clinical Oncology</i> , 2017, 22, 476-483.	2.2	73
129	The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy. <i>International Journal of Clinical Oncology</i> , 2017, 22, 887-896.	2.2	17
130	Clinicopathological significance and impact on outcomes of the gene expression levels of IGF-1, IGF-2 and IGF-1R, IGFBP-3 in patients with colorectal cancer: Overexpression of the IGFBP-3 gene is an effective predictor of outcomes in patients with colorectal cancer. <i>Oncology Letters</i> , 2017, 13, 3958-3966.	1.8	22
131	Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine. <i>Oncology Letters</i> , 2017, 13, 3423-3430.	1.8	6
132	Evaluation of short-term outcomes of laparoscopic-assisted surgery for colorectal cancer in elderly patients aged over 75 years old: a multi-institutional study (YSURG1401). <i>BMC Surgery</i> , 2017, 17, 29.	1.3	32
133	Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. <i>Annals of Surgery</i> , 2017, 265, 277-283.	4.2	243
134	Clinical impact of tumor location on the colon cancer survival and recurrence: analyses of pooled data from three large phase III randomized clinical trials. <i>Cancer Medicine</i> , 2017, 6, 2523-2530.	2.8	21
135	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2461-2471.	13.7	1,749
136	Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemotherapy. <i>Oncology Letters</i> , 2017, 14, 1505-1511.	1.8	7
137	Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients' data from three large phase III randomized trials. <i>Cancer Medicine</i> , 2017, 6, 1573-1580.	2.8	73
138	Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant chemotherapy. <i>Oncology Letters</i> , 2017, 14, 599-606.	1.8	7
139	Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab- \neg ve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-102). <i>International Journal of Cancer</i> , 2017, 140, 188-196.	5.1	27
140	Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer: Japan Clinical Oncology Group Study JCOG0912. <i>Gastric Cancer</i> , 2017, 20, 699-708.	5.3	288
141	Prediction of postoperative inflammatory complications after esophageal cancer surgery based on early changes in the C-reactive protein level in patients who received perioperative steroid therapy and enhanced recovery after surgery care: a retrospective analysis. <i>BMC Cancer</i> , 2017, 17, 812.	2.6	9
142	Development and validation of a prognostic nomogram for colorectal cancer after radical resection based on individual patient data from three large-scale phase III trials. <i>Oncotarget</i> , 2017, 8, 99150-99160.	1.8	5
143	Evaluation of safety, feasibility and the long-term outcomes of colectomy for colorectal adenocarcinoma in patients older than 80 years of age. <i>Molecular and Clinical Oncology</i> , 2017, 7, 564-568.	1.0	1
144	C-Reactive Protein Was an Early Predictor of Postoperative Infectious Complications After Pancreaticoduodenectomy for Pancreatic Cancer. <i>International Surgery</i> , 2017, 102, 258-266.	0.1	0

#	ARTICLE	IF	CITATIONS
145	Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials. <i>Journal of Cancer</i> , 2017, 8, 4057-4064.	2.5	15
146	Effectiveness of alendronate for bone disorder after gastrectomy for gastric cancer. <i>Asian Journal of Surgery</i> , 2017, 40, 470-474.	0.4	5
147	Phase III trial to evaluate the efficacy of neoadjuvant chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy with adjuvant S-1 in locally advanced gastric cancer: Japan Clinical Oncology Group study JCOG1509 (NAGISA trial).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4134-TPS4134.	1.6	19
148	Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2-2.	1.6	64
149	Primary results of a phase III trial to evaluate bursectomy for patients with subserosal/serosal gastric cancer (JCOG1001).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5-5.	1.6	11
150	Effectiveness and limitations of staging laparoscopy for peritoneal metastases in advanced gastric cancer from the results of JCOG0501: A randomized trial of gastrectomy with or without neoadjuvant chemotherapy for type 4 or large type 3 gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9-9.	1.6	3
151	Clinical Significance of INHBA Gene Expression in Patients with Gastric Cancer who Receive Curative Resection Followed by Adjuvant S-1 Chemotherapy. <i>In Vivo</i> , 2017, 31, 565-571.	1.3	29
152	Clinical Significance of Tensin 4 Gene Expression in Patients with Gastric Cancer. <i>In Vivo</i> , 2017, 31, 1065-1071.	1.3	12
153	Randomized controlled Phase III study comparing hepatic arterial infusion with systemic chemotherapy after curative resection for liver metastasis of colorectal carcinoma: JFMC 29â€“0003. <i>Journal of Cancer Research and Therapeutics</i> , 2017, 13, 84.	0.9	15
154	A Case Duodenal Neuroendocrine Tumor: A Primary Tumor Site Recognized 30 Months after the Excision of Isolated Lymph Node Metastasis. <i>Japanese Journal of Gastroenterological Surgery</i> , 2017, 50, 429-436.	0.1	1
155	Pathological tumor size is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with S-1. <i>Annals of Cancer Research and Therapy</i> , 2017, 25, 5-11.	0.3	0
156	Meta-analysis of Patient-level Data on Therapeutic Effects of TJ-14 (Hangeshashinto) for Gastroenterological Cancer Chemotherapy-induced Severe Oral Mucositis with the HANGESHA-G and HANGESHA-Cs : protocol paper. <i>Annals of Cancer Research and Therapy</i> , 2017, 25, 92-94.	0.3	0
157	Clinical trial comparing UFT-PSK combination adjuvant therapy and surgery-alone for Stage II rectal cancer. <i>Annals of Cancer Research and Therapy</i> , 2017, 25, 15-16.	0.3	1
158	The relation between postoperative surgical complications and gastric cancer survival. <i>Annals of Cancer Research and Therapy</i> , 2017, 25, 88-89.	0.3	0
159	The Neoadjuvant Imatinib Therapy Allowing for the Curative Resection of an Unresectable Duodenum GIST: A Case Report. <i>Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)</i> , 2017, 41, 949-954.	0.0	0
160	The short- and long-term outcomes of pancreatic resection for pancreatic adenocarcinoma in patients older than 75 years.. <i>Journal of Clinical Oncology</i> , 2017, 35, 470-470.	1.6	0
161	Enteral feeding tube insertion after esophagectomy: Technique via transgastric conduit or transduodenal.. <i>Journal of Clinical Oncology</i> , 2017, 35, 210-210.	1.6	0
162	The impact of SPARC expression in survival of pancreatic ductal adenocarcinoma patients after curative resection.. <i>Journal of Clinical Oncology</i> , 2017, 35, 321-321.	1.6	0

#	ARTICLE	IF	CITATIONS
163	The surgical Apgar score is an independent prognostic factor in patients with pancreatic cancer undergoing pancreaticoduodenectomy followed by adjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 472-472.	1.6	0
164	A prospective multicenter observational study of surgical palliation examining postoperative quality of life in patients treated for malignant gastric outlet obstruction caused by incurable advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6-6.	1.6	2
165	Non-Randomized Confirmatory Trial of Laparoscopy-Assisted Total Gastrectomy and Proximal Gastrectomy with Nodal Dissection for Clinical Stage I Gastric Cancer: Japan Clinical Oncology Group Study JCOG1401. <i>Journal of Gastric Cancer</i> , 2016, 16, 93.	2.5	22
166	Risk factors associated with recurrence by peritoneal dissemination or paraaortic lymph node metastasis after curative surgery in patients with colorectal cancer. <i>Annals of Cancer Research and Therapy</i> , 2016, 24, 58-59.	0.3	2
167	Risk Assessment of Pancreatic Surgery by Surgical Apgar Score and Body Mass Index. <i>International Surgery</i> , 2016, 101, 263-269.	0.1	3
168	Validity of the Japanese version of functional assessment of cancer therapy-gastric (FACT-Ga) and its sensitivity to ascites volume change: a retrospective analysis of Japanese clinical trial participants. <i>Supportive Care in Cancer</i> , 2016, 24, 4515-4521.	2.2	5
169	Feasibility and Safety of Transhiatal Approach and D2 Total Gastrectomy after Neoadjuvant Chemotherapy for Adenocarcinoma of the Esophago-Gastric Junction: A Subset Analysis of the COMPASS Trial. <i>Digestive Surgery</i> , 2016, 33, 424-430.	1.2	4
170	Apatinib “ new third-line option for refractory gastric or GEJ cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 268-270.	27.6	37
171	Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer. <i>European Journal of Cancer</i> , 2016, 62, 103-111.	2.8	39
172	Usefulness of Surgical Apgar Score on Predicting Survival After Surgery for Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 757-763.	1.5	10
173	Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701). <i>European Journal of Cancer</i> , 2016, 65, 164-171.	2.8	40
174	The Short- and Long-Term Outcomes of Pancreatic Resection for Pancreatic Adenocarcinoma in Patients Older Than 75 Years. <i>International Surgery</i> , 2016, 101, 554-561.	0.1	1
175	Feasibility and Safety of Laparoscopy-Assisted Subtotal Gastrectomy for Gastric Cancer Invading the Upper Stomach. <i>International Surgery</i> , 2016, 101, 577-582.	0.1	0
176	An Institutional Experience of Introducing an Enhanced Recovery After Surgery (ERAS) Program for Pancreaticoduodenectomy. <i>International Surgery</i> , 2016, 101, 542-549.	0.1	1
177	Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan. <i>Ecological Management and Restoration</i> , 2016, 30, n/a-n/a.	0.4	21
178	Theoretical therapeutic impact of lymph node dissection on adenocarcinoma and squamous cell carcinoma of the esophagogastric junction. <i>Gastric Cancer</i> , 2016, 19, 143-149.	5.3	43
179	The survival difference between gastric cancer patients from the UK and Japan remains after weighted propensity score analysis considering all background factors. <i>Gastric Cancer</i> , 2016, 19, 479-489.	5.3	22
180	Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 309-318.	10.7	560

#	ARTICLE	IF	CITATIONS
181	Risk Factors for the Loss of Lean Body Mass After Gastrectomy for Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 1963-1970.	1.5	33
182	Clinicopathological Characteristics and Prognostic Factors of Patients with Siewert Type II Esophagogastric Junction Carcinoma: A Retrospective Multicenter Study. <i>World Journal of Surgery</i> , 2016, 40, 1672-1679.	1.6	30
183	Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101). <i>Gastric Cancer</i> , 2016, 19, 839-851.	5.3	51
184	Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference. <i>Gastric Cancer</i> , 2016, 19, 15-20.	5.3	51
185	Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 415-422.	2.5	11
186	Impact of preoperative hand grip strength on morbidity following gastric cancer surgery. <i>Gastric Cancer</i> , 2016, 19, 1008-1015.	5.3	66
187	Quality of life and nutritional consequences after aboral pouch reconstruction following total gastrectomy for gastric cancer: randomized controlled trial CCG1101. <i>Gastric Cancer</i> , 2016, 19, 977-985.	5.3	26
188	Body composition analysis within 1 month after gastrectomy for gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 645-650.	5.3	50
189	Impact of preoperative sarcopenia on recurrence in gastric cancer surgery. <i>Journal of Clinical Oncology</i> , 2016, 34, 120-120.	1.6	1
190	Changes of weight and body composition after gastrectomy in the elderly gastric cancer patients. <i>Journal of Clinical Oncology</i> , 2016, 34, 89-89.	1.6	2
191	Clinical features of colorectal mucinous and poorly differentiated adenocarcinomas; study concept of a propensity score analysis in a pooled data of 5530 patients. <i>Annals of Cancer Research and Therapy</i> , 2016, 24, 52-53.	0.3	1
192	The relation between postoperative surgical complications and colorectal cancer survival. <i>Annals of Cancer Research and Therapy</i> , 2016, 24, 54-55.	0.3	1
193	Comparison of clinic pathological characters and survival between right- and left-side colon cancer. <i>Annals of Cancer Research and Therapy</i> , 2016, 24, 62-63.	0.3	2
194	Hazard rate of tumor recurrence over time: a pooled-analysis of three clinical trials with fluoropyrimidine-based adjuvant chemotherapy for colorectal cancer achieved by the Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC). <i>Annals of Cancer Research and Therapy</i> , 2016, 24, 60-61.	0.3	0
195	Prognostic Nomogram for Colorectal Cancer after Radical Resection in Japanese population. <i>Annals of Cancer Research and Therapy</i> , 2016, 24, 56-57.	0.3	0
196	Multimodal analgesia combined with intravenous administration of acetaminophen in perioperative management of esophagectomy using modified ERAS protocol. <i>Journal of Clinical Oncology</i> , 2016, 34, 94-94.	1.6	1
197	Survival and prognosticators of gastric cancer patients with only positive peritoneal lavage cytology. <i>Journal of Clinical Oncology</i> , 2016, 34, 16-16.	1.6	0
198	Effects of perioperative enteral EPA-enriched immunonutrition on meaningful loss of lean body mass after total gastrectomy for gastric cancer: Post hoc analysis of a phase III study. <i>Journal of Clinical Oncology</i> , 2016, 34, 85-85.	1.6	0

#	ARTICLE	IF	CITATIONS
199	Safety and feasibility of enhanced recovery after surgery in the patients underwent pancreaticoduodenectomy for hepatobiliary and pancreatic malignancy.. Journal of Clinical Oncology, 2016, 34, 338-338.	1.6	0
200	C-reactive protein at 4 days after surgery as an early predictor of serious infectious complications following esophageal cancer surgery.. Journal of Clinical Oncology, 2016, 34, 10-10.	1.6	0
201	Subset of patients with unfavorable T1N2-3M0 gastric cancer for whom surgery alone is the standard treatment.. Journal of Clinical Oncology, 2016, 34, 105-105.	1.6	0
202	Safety and feasibility of laparoscopic surgery for colorectal cancer in elderly patients (YSURG1401) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	0
203	Lymphatic invasion as an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.. Journal of Clinical Oncology, 2016, 34, 290-290.	1.6	0
204	Risk factors for loss of lean body mass after gastrectomy for gastric cancer.. Journal of Clinical Oncology, 2016, 34, 79-79.	1.6	0
205	A randomized phase II trial of systemic chemotherapy with or without trastuzumab followed by surgery in HER2 positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger study).. Journal of Clinical Oncology, 2016, 34, TPS4143-TPS4143.	1.6	0
206	The Surgical Apgar Score Is an Independent Prognostic Factor in Patients with Pancreatic Cancer Undergoing Pancreatoduodenectomy Followed by Adjuvant Chemotherapy. Anticancer Research, 2016, 36, 2497-503.	1.1	5
207	Easy method for fixation of the anvil using a one-handed sliding knot technique after laparoscopic total gastrectomy. Asian Journal of Endoscopic Surgery, 2015, 8, 483-486.	0.9	1
208	The short- and long-term outcomes of radical antegrade modular pancreateosplenectomy for adenocarcinoma of the body and tail of the pancreas. BMC Surgery, 2015, 15, 120.	1.3	16
209	Surgical Site Infection and Antimicrobial Prophylaxis. The Journal of Japan Society for Clinical Anesthesia, 2015, 35, 049-055.	0.0	0
210	Pulmonary Tumor Thrombotic Microangiopathy Associated with Gastric Cancer Diagnosed during Life. Japanese Journal of Gastroenterological Surgery, 2015, 48, 817-824.	0.1	1
211	A Spontaneous Rupture of the Esophagus Treated with Primary Closure under Thoracoscopic Surgery. Japanese Journal of Gastroenterological Surgery, 2015, 48, 186-191.	0.1	3
212	Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut, 2015, 64, 1721-1731.	12.1	197
213	Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer. Annals of Surgical Oncology, 2015, 22, 2560-2566.	1.5	97
214	Mediastinal lymph node metastasis and recurrence in adenocarcinoma of the esophagogastric junction. Surgery, 2015, 157, 551-555.	1.9	87
215	Technical Reproducibility of Single-Nucleotide and Size-Based DNA Biomarker Assessment Using DNA Extracted from Formalin-Fixed, Paraffin-Embedded Tissues. Journal of Molecular Diagnostics, 2015, 17, 242-250.	2.8	8
216	Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial. European Journal of Cancer, 2015, 51, 808-816.	2.8	40

#	ARTICLE	IF	CITATIONS
217	A phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer (JCOG0912): Analysis of the safety and short-term clinical outcomes.. Journal of Clinical Oncology, 2015, 33, 4017-4017.	1.6	4
218	Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma (JCOG0110): Final survival analysis.. Journal of Clinical Oncology, 2015, 33, 103-103.	1.6	10
219	A randomized phase II trial of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment versus SP randomized PII trial (XParTS II).. Journal of Clinical Oncology, 2015, 33, 105-105.	1.6	5
220	Long-term survival results of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: A multicenter phase II trial (JCOG 0703).. Journal of Clinical Oncology, 2015, 33, 113-113.	1.6	1
221	A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer who relapsed after S-1 adjuvant therapy, XP after TS-1 adjuvant failure (XParTS).. Journal of Clinical Oncology, 2015, 33, 124-124.	1.6	1
222	Prognostic impact of postoperative morbidity after esophagectomy for esophageal cancer: Supplementary exploratory analysis of JCOG9907.. Journal of Clinical Oncology, 2015, 33, 155-155.	1.6	2
223	EWSurgical Apgar score predicts postoperative complications after surgery for gastric cancer. Global Surgery (London), 2015, 1, .	0.0	2
224	Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients.. Journal of Clinical Oncology, 2015, 33, 486-486.	1.6	0
225	Long-term survival results of the patients who were enrolled to the feasibility study of laparoscopy-assisted distal gastrectomy for c-stage I gastric cancer.. Journal of Clinical Oncology, 2015, 33, 166-166.	1.6	0
226	Risk factors for severe weight loss after gastrectomy for gastric cancer.. Journal of Clinical Oncology, 2015, 33, 38-38.	1.6	0
227	Surgery for solitary pulmonary metastasis after curative gastrectomy for gastric cancer: Contribution to the long-term survival.. Journal of Clinical Oncology, 2015, 33, 102-102.	1.6	0
228	Long-Term Survival of a Case with Advanced Pancreatic Cancer Involving Para-Aortic Lymph Node Metastasis Treated with Multidisciplinary Therapy. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese) Tj ETQq0 000gBT /Overlock 10		
229	Changes of body weight and composition after gastric cancer surgery. The Japanese Journal of SURGICAL METABOLISM and NUTRITION, 2015, 49, 205-211.	0.1	2
230	Loss of lean body mass within one week as a major determinant for total weight loss at one month after gastrectomy for gastric cancer.. Journal of Clinical Oncology, 2015, 33, 219-219.	1.6	0
231	Perioperative management of esophageal cancer surgery based on a modified ERAS protocol.. Journal of Clinical Oncology, 2015, 33, 99-99.	1.6	0
232	Impact of postoperative complications on pancreatic cancer survival and recurrence.. Journal of Clinical Oncology, 2015, 33, 446-446.	1.6	1
233	Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer.. Journal of Clinical Oncology, 2015, 33, 471-471.	1.6	0
234	Bronchogenic Cyst in the Stomach. Japanese Journal of Gastroenterological Surgery, 2015, 48, 399-406.	0.1	1

#	ARTICLE	IF	CITATIONS
235	The feasibility and safety conversion surgery in stage IV gastric cancer.. Journal of Clinical Oncology, 2015, 33, 164-164.	1.6	0
236	An Adult Case of Intussusception Caused by an Inverted Meckel's Diverticulum without Gastrointestinal Tissue. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2015, 40, 81-84.	0.0	0
237	Effects of a planned preoperative exercise program on body composition in early gastric cancer patients with metabolic syndrome.. Journal of Clinical Oncology, 2015, 33, 206-206.	1.6	0
238	A randomized 2X2 phase II trial comparing two and four courses of S-1/cisplatin (SC) and paclitaxel/cisplatin (PC) as neoadjuvant chemotherapy for locally resectable advanced gastric cancer: Survival results of COMPASS.. Journal of Clinical Oncology, 2015, 33, 111-111.	1.6	0
239	Subset analysis of COMPASS: A randomized 2X2 phase II trial comparing two and four courses of S-1/cisplatin (SC) and paclitaxel/cisplatin (PC) as neoadjuvant chemotherapy for locally advanced gastric cancer.. Journal of Clinical Oncology, 2015, 33, e15067-e15067.	1.6	0
240	Conversion surgery for stage IV gastric cancer: Feasibility, safety, and efficacy results.. Journal of Clinical Oncology, 2015, 33, e15031-e15031.	1.6	0
241	Stratification markers for the risk of recurrence after curative resection of stage II or III gastric cancer and potential clinical applications.. Journal of Clinical Oncology, 2015, 33, 11040-11040.	1.6	0
242	Impact of postoperative complications on survival and recurrence in pancreatic cancer. Anticancer Research, 2015, 35, 2401-9.	1.1	34
243	Prediction of Gastric Cancer Development by Serum Pepsinogen Test and Helicobacter pylori Seropositivity in Eastern Asians: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e109783.	2.5	83
244	Neoadjuvant chemotherapy for gastric cancer in Japan: a standing position by comparing with adjuvant chemotherapy. Surgery Today, 2014, 44, 11-21.	1.5	59
245	Induction of a Pathological Complete Response by Four Courses of Neoadjuvant Chemotherapy for Gastric Cancer: Early Results of the Randomized Phase II COMPASS Trial. Annals of Surgical Oncology, 2014, 21, 213-219.	1.5	64
246	Randomized Comparison of Surgical Stress and the Nutritional Status Between Laparoscopy-Assisted and Open Distal Gastrectomy for Gastric Cancer. Annals of Surgical Oncology, 2014, 21, 1983-1990.	1.5	34
247	Feasibility of enhanced recovery after surgery in gastric surgery: a retrospective study. BMC Surgery, 2014, 14, 41.	1.3	37
248	Vitamin E Deficiency Begins within 6 Months after Gastrectomy for Gastric Cancer. World Journal of Surgery, 2014, 38, 2065-2069.	1.6	6
249	Accuracy of CT Staging of Locally Advanced Gastric Cancer after Neoadjuvant Chemotherapy: Cohort Evaluation within a Randomized Phase II Study. Annals of Surgical Oncology, 2014, 21, 385-389.	1.5	38
250	Methylene blue-assisted technique for harvesting lymph nodes after radical surgery for gastric cancer: a prospective randomized phase III study. BMC Cancer, 2014, 14, 155.	2.6	4
251	Exploratory Analysis to Find Unfavorable Subset of Stage II Gastric Cancer for Which Surgery Alone Is the Standard Treatment; Another Target for Adjuvant Chemotherapy. International Surgery, 2014, 99, 835-841.	0.1	3
252	Efficacy and safety result of trastuzumab (T-mab) and paclitaxel for T-mab naive patients with HER2-positive previously treated advanced or recurrent gastric cancer (JFMC45-1102): Final report.. Journal of Clinical Oncology, 2014, 32, 79-79.	1.6	2

#	ARTICLE	IF	CITATIONS
253	Prognostic factors in stage IB gastric cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 6580.	3.3	18
254	Harvesting lymph nodes in gastric cancer surgery: A prospective randomized controlled study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 28-28.	1.6	0
255	A prospective observational study on chemotherapy-induced nausea and vomiting for esophageal cancer patients in Japan.. <i>Journal of Clinical Oncology</i> , 2014, 32, 135-135.	1.6	0
256	Three Cases of Advanced Gastric Cancer Confirmed as pathological Complete Response following Neoadjuvant Chemotherapy and Gastric Resection. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan)</i> Tj ETQq0 0 0.gBT /Overlock 10 T	1.6	0
257	Prognostic and predictive value of tumor-infiltrating immune cells in Japanese patients with stage II/III gastric cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 46-46.	1.6	1
258	Impact of preoperative sarcopenia on morbidity in gastric cancer surgery.. <i>Journal of Clinical Oncology</i> , 2014, 32, 40-40.	1.6	0
259	Coamplification of receptor tyrosine kinases and downstream targets in Japanese gastric cancers.. <i>Journal of Clinical Oncology</i> , 2014, 32, 41-41.	1.6	0
260	Risk factors for surgical complications after D2 gastrectomy following neoadjuvant chemotherapy for gastric cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 164-164.	1.6	0
261	Long-term follow-up of advanced gastric cancer patients who achieved a pathologic complete response with neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 133-133.	1.6	0
262	Matched pair analysis to examine the effects of a planned preoperative exercise program in early gastric cancer patients with metabolic syndrome to reduce operative risk: The Adjuvant Exercise for General Elective Surgery (AEGES) study group.. <i>Journal of Clinical Oncology</i> , 2014, 32, 166-166.	1.6	0
263	Prediction of nodal metastasis in clinical T1 gastric cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 21-21.	1.6	0
264	The survival difference between gastric cancer patients from the United Kingdom and Japan after using weighted propensity score for adjustment of differing background factors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4055-4055.	1.6	0
265	Priority of Lymph Node Dissection for Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction. <i>Annals of Surgical Oncology</i> , 2013, 20, 4252-4259.	1.5	49
266	Laparoscopic esophagojejunostomy using the EndoStitch and a circular stapler under a direct view created by the ENDOCAMELEON. <i>Gastric Cancer</i> , 2013, 16, 609-614.	5.3	17
267	Body Weight Loss After Surgery is an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 2000-2006.	1.5	135
268	A prospective feasibility and safety study of laparoscopy-assisted distal gastrectomy for clinical stage I gastric cancer initiated by surgeons with much experience of open gastrectomy and laparoscopic surgery. <i>Gastric Cancer</i> , 2013, 16, 126-132.	5.3	36
269	Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer. <i>Gastric Cancer</i> , 2013, 16, 133-139.	5.3	32
270	A Phase III Study of Laparoscopy-assisted Versus Open Distal Gastrectomy with Nodal Dissection for Clinical Stage IA/IB Gastric Cancer (JCOG0912). <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 324-327.	1.3	122

#	ARTICLE	IF	CITATIONS
271	A Randomized Phase II Trial of Omentum-preserving Gastrectomy for Advanced Gastric Cancer. Japanese Journal of Clinical Oncology, 2013, 43, 214-216.	1.3	19
272	Clinical significance of SPARC gene expression in patients with gastric cancer. Journal of Surgical Oncology, 2013, 108, 364-368.	1.7	30
273	Positive reactions of hospital staff to feedback by specialists.. Journal of Clinical Oncology, 2013, 31, 57-57.	1.6	1
274	Improvement of Adverse Effects by Juzen-taiho-to in the Chemotherapy for Patients with Advanced or Recurrent Gastric Cancer. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2013, 38, 62-66.	0.0	0
275	Induction of pathologic complete response by long-term neoadjuvant chemotherapy for gastric cancer: Early results of a randomized phase II studyâ€”A COMPASS trial.. Journal of Clinical Oncology, 2013, 31, 71-71.	1.6	0
276	A prospective cohort study to reduce operative risk in stage I gastric cancer patients with metabolic syndrome: Preoperative exercise versus surgery alone.. Journal of Clinical Oncology, 2013, 31, e15112-e15112.	1.6	0
277	A Phase III Trial to Evaluate the Effect of Perioperative Nutrition Enriched with Eicosapentaenoic Acid on Body Weight Loss after Total Gastrectomy for T2-T4a Gastric Cancer. Japanese Journal of Clinical Oncology, 2012, 42, 459-462.	1.3	15
278	A Comparison of Multimodality Treatment: Two and Four Courses of Neoadjuvant Chemotherapy Using S-1/CDDP or S-1/CDDP/Docetaxel Followed by Surgery and S-1 Adjuvant Chemotherapy for Macroscopically Resectable Serosa-positive Gastric Cancer: A Randomized Phase II Trial (COMPASS-D) Tj ETQq0 0 0 rGBT /Overlock 10 TF	1.3	16
279	Laparoscopic or Open Distal Gastrectomy After Neoadjuvant Chemotherapy for Operable Gastric Cancer, a Randomized Phase II Trial (LANDSCOPE Trial). Japanese Journal of Clinical Oncology, 2012, 42, 654-657.	1.3	11
280	A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II). BMC Cancer, 2012, 12, 307.	2.6	12
281	Usefulness of enhanced recovery after surgery protocol as compared with conventional perioperative care in gastric surgery. Gastric Cancer, 2012, 15, 34-41.	5.3	141
282	Macroscopic tumor size as an independent prognostic factor for patients with stage II/III gastric cancer who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.. Journal of Clinical Oncology, 2012, 30, 56-56.	1.6	0
283	A Randomized Phase II Trial to Test the Efficacy of Intra-peritoneal Paclitaxel for Gastric Cancer with High Risk for the Peritoneal Metastasis (INPACT Trial). Japanese Journal of Clinical Oncology, 2011, 41, 283-286.	1.3	18
284	A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703). Gastric Cancer, 2010, 13, 197-203.	5.3	39
285	Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG 0703). Gastric Cancer, 2010, 13, 238-244.	5.3	297
286	A Comparison of Multimodality Treatment: Two or Four Courses of Paclitaxel plus Cisplatin or S-1 plus Cisplatin Followed by Surgery for Locally Advanced Gastric Cancer, a Randomized Phase II Trial (COMPASS). Japanese Journal of Clinical Oncology, 2010, 40, 369-372.	1.3	22
287	Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer. Gastric Cancer, 2009, 12, 31-36.	5.3	25
288	A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer, 2009, 12, 212-218.	5.3	5

#	ARTICLE	IF	CITATIONS
289	A phase I study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 1071-1077.	2.3	9
290	Strangulation necrosis of the intestine in a patient with giant polycystic kidney disease: a rare cause of acute abdomen. <i>International Surgery</i> , 2008, 93, 15-8.	0.1	2
291	Protein levels of tissue inhibitor of metalloproteinase-1 in tumor extracts as a marker for prognosis and recurrence in patients with gastric cancer. <i>Gastric Cancer</i> , 2006, 9, 106-113.	5.3	18
292	Up-regulation of hypoxia-inducible factor-1 alpha and VEGF mRNAs in peritoneal dissemination of patients with gastric cancer. <i>Anticancer Research</i> , 2006, 26, 3849-53.	1.1	16
293	Expression of MMP-7 and MT1-MMP in peritoneal dissemination of gastric cancer. <i>Hepato-Gastroenterology</i> , 2006, 53, 964-7.	0.5	5
294	Induction of lymphokine-activated cytotoxic T lymphocytes stimulated by dendritic cells and autologous tumor from a patient with gastric cancer and their effects in vitro. <i>Hepato-Gastroenterology</i> , 2005, 52, 289-92.	0.5	1
295	Is bursectomy necessary for patients with gastric cancer invading the serosa?. <i>Hepato-Gastroenterology</i> , 2004, 51, 1524-6.	0.5	7
296	Effects of TS-1 on peritoneal dissemination of gastric cancer in nude mice. <i>Hepato-Gastroenterology</i> , 2004, 51, 1554-7.	0.5	1
297	Peritoneal cytology in patients with gastric cancer exposed to the serosa—a proposed new classification based on the local and distant cytology. <i>Hepato-Gastroenterology</i> , 2003, 50, 1183-6.	0.5	8
298	Should gastric cancer with peritoneal metastasis be treated surgically?. <i>Hepato-Gastroenterology</i> , 2003, 50, 1712-5.	0.5	13
299	Indications of limited surgery for gastric cancer with submucosal invasion—analysis of 715 cases with special reference to site of the tumor and level 2 lymph nodes. <i>Hepato-Gastroenterology</i> , 2003, 50, 1727-30.	0.5	5
300	A combination immunochemotherapy of 5-fluorouracil, cisplatin, leucovorin, and OK-432 for advanced and recurrent gastric carcinoma. <i>Hepato-Gastroenterology</i> , 2003, 50, 2259-63.	0.5	3
301	Is D2 lymph node dissection necessary for early gastric cancer?. <i>Annals of Surgical Oncology</i> , 2002, 9, 401-405.	1.5	60
302	Advanced gastric carcinoma successfully treated with TS-1 as neoadjuvant chemotherapy. <i>Gastric Cancer</i> , 2000, 3, 171-175.	5.3	6
303	Tissue inhibitor of matrix metalloproteinase-1 in the plasma of patients with gastric carcinoma. , 1999, 86, 1929-1935.		28
304	Insulin Resistance and the Alterations of Glucose Transporterâ€”4 in Adipose Cells From Cachectic Tumorâ€”Bearing Rats. <i>Journal of Parenteral and Enteral Nutrition</i> , 1997, 21, 347-349.	2.6	3
305	Long-term effect of radical gastrectomy on nutrition and immunity. <i>Surgery Today</i> , 1993, 23, 320-324.	1.5	21
306	CLINICAL INVESTIGATION OF BONE METASTASIS FROM DIFFERENTIATED CARCINOMA OF THE THYROID. <i>The Journal of the Japanese Practical Surgeon Society</i> , 1992, 53, 287-291.	0.0	0

#	ARTICLE	IF	CITATIONS
307	A CASE OF UNDIFFERENTIATED CARCINOMA OF THE THYROID WITH A MUCOEPIDERMOID CARCINOMA. The Journal of the Japanese Practical Surgeon Society, 1991, 52, 2042-2046.	0.0	0
308	A CASE OF PAPILLARY CARCINOMA OF THE THYROID ASSOCIATED WITH PRIMARY HYPERTHYROIDISM. The Journal of the Japanese Practical Surgeon Society, 1991, 52, 2346-2350.	0.0	0
309	Self-defensive response to bone disorder after gastric cancer surgery. Clinical and Experimental Medical Sciences, 0, 2, 1-10.	0.4	3
310	Usefulness of an S-1 dosage formula: an exploratory analysis of randomized clinical trial (JCOG1001). Gastric Cancer, 0, , .	5.3	0